搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
HealthDay on MSN
2 天
Pembrolizumab + Chemo Beneficial for Early-Stage Triple-Negative Breast Cancer
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...
8 天
全球首款mRNA肿瘤疫苗预计最早在2025年上市!我国mRNA技术迅猛发展
由此可见,mRNA-4157(V940)联合帕博利珠单抗在黑色素瘤患者中耐受性良好。 而mRNA-4157(V940)预计最早在2025年上市,这将会是全球首款mRNA肿瘤疫苗。
17 天
晚期癌症总生存期几乎翻倍,Nectin-4靶向ADC免疫组合疗法在欧盟获批上市
默沙东正与辉瑞和安斯泰来合作,针对这一组合进行评估,将其作为尿路上皮癌多阶段广泛临床开发计划的一部分,其中包括两项针对肌层浸润性膀胱癌的3期临床试验正在进行中,即KEYNOTE-B15和KEYNOTE-905试验。
Medscape
3 天
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Medpage Today on MSN
5 天
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer
Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...
11 天
九月第二周的意外“黑马”,股价领涨美股,单日暴增56%
周一,Summit Therapeutics (SMMT.US)股价一路暴涨。截至发稿,该股涨幅达55.99%,报19.14美元。这是自2017年9月11日收于16.00美元以来的首次创纪录收盘新高,而且,今年迄今为止增长了632.38%。
Medscape
5 天
Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
oncnursingnews
7 天
Pembrolizumab Plus Chemoradiotherapy May Be New Standard in Locally Advanced Cervical Cancer
Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...
oncnursingnews
6 天
Perioperative Pembrolizumab Improves Survival in Early-Stage TNBC
Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...
emjreviews.com
7 天
Pembrolizumab with Chemoradiotherapy Improves Cervical Cancer Survival: ESMO 2024
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
阿思達克財經網
13 天
抗癌药物取得进展 Summit Therapeutics(SMMT.US)盘前一度涨超50%
在初步分析中,与单一疗法pembrolizumab相比,ivonescimab单药治疗在试验的主要终点无进展生存期方面表现出统计学上显着改善,从而成为在 NSCLC 随机后期临床试验中第一个比pembrolizumab获得临床意义益处的药物。
Targeted Oncology
7 天
Extended Follow-Up Bolsters Adjuvant Pembrolizumab DFS Rate in MIUC
Longer follow-up from the phase 3 AMBASSADOR trial showed adjuvant pembrolizumab to demonstrate a statistically significant ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈